Oral Ketamine for Control of Chronic Pain in Children

Phase 1

Completed

Conditions: Chronic Pain

Interventions: Drug: Ketamine

Registration Number: NCT01369680

Lead Sponsor: University of Rochester

Brief Summary: The study is a maximum tolerated dose finding study for oral, chronic, daily administration of oral ketamine (by mouth) in children with long-term daily pain.

Detailed Description: Pain control in children is a major concern when children have chronic diseases, such as cancer and sickle cell disease with frequent pain crises. Additionally, though the traditional pain medications of morphine and acetaminophen are regarded as safe and effective for pain control in children, there are few alternative therapies available when these medications are insufficient. Chronic pain (whether cancer or non-cancer pain) in children has few approved and well tolerated therapeutic options with proven efficacy.

Ketamine is a medication that was first described in 1962\[1\]. It is an NMDA-R (N-methyl-D-aspartate-receptor) antagonist with dissociative amnestic and analgesic effects\[1-2\]. Ketamine is particularly successful as a dissociative amnestic for children in the emergent setting as it has little respiratory or cardiac impact, has a short half-life, and has fewer psychomimetic effects in the pediatric population than in adults\[1\]. Its function is via antagonism and reduction of NMDA-receptors in the afferent pain pathway. In effect, this decreases pain receptors and can dramatically reduce the need for narcotic pain medications for patients with chronic pain.

Unfortunately, with such dissociative effects, ketamine has been a drug of abuse for decades\[1,3\]. Additionally, there is concern that ketamine may have long-term deleterious effects on cognition for those subjects chronically exposed to IV ketamine\[4\], especially children whose neural pathways may still be developing\[1,5\]. These effects may include difficulty with attention and working memory, though the effects appear to be short-term and reversible in adults. However, much of this data is derived from rodent or primate studies, and there is little evidence that there are long-term cognitive effects on humans chronically exposed to ketamine\[1\]. This lack of data is particularly impactful in the pediatric group.

Ketamine has been evaluated as an analgesic medication for patients with chronic pain that is not resolved with narcotics and gabapentin. There are a number of case reports and small case series that suggest ketamine is a useful medication for control of chronic pain in adults\[2,4,6-8\]. Additionally, there are case studies that describe lasting (12 week) pain control in adults after 4-10 days of ketamine therapy\[7-8\]. However, there are, to date, little data that aid a pediatrician in determining if ketamine is a safe and effective option as a chronic, oral therapy for children with chronic pain.

Overall, there are few proven safe and effective medications for use in chronic pain management for children. Ketamine is a well known medication with a well elaborated safety profile, when given intravenously and for short periods of time. There is, as above, emerging data that ketamine is useful for chronic pain control in adults. The question that remains to be answered is whether ketamine is a safe option for chronic use in children, whose brains are significantly more plastic and whose metabolism is different compared with those of adults.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 12

Inclusion Criteria

Subject, parent, or guardian willing and able to give informed consent
NRS for pain >4
Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis
Chronic pain related to diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)
Able to tolerate and cooperate with neurocognitive assessment
Age 8-22 years old

Exclusion Criteria

If they are known or suspected to have drug dependence or addiction
History of psychiatric disorder such as depression, schizophrenia, or bipolar disorder
History of hypertension
Unable to cooperate with neurocognitive assessment
Chronic pain related to chronic abdominal pain syndrome
Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.
Previous intolerance or allergic reaction to ketamine
Pregnancy
Use of CYP3A4 inhibitors or inducers within the 2 week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ketamine 0.25 mg/kg/dose	Ketamine	The first three subjects were administered 0.25 mg/kg/dose oral ketamine.
Ketamine 0.5 mg/kg/dose	Ketamine	The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.
Ketamine 1.5 mg/kg/dose	Ketamine	The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.
Ketamine 1 mg/kg/dose	Ketamine	The third group of three subjects were administered 1 mg/kg/dose oral ketamine.

Primary Outcome Measures

Name	Time	Method
Number of Participants Tolerating Dose	Up to 2 weeks	According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity.

Secondary Outcome Measures

Name	Time	Method
Neurocognitive Effect	At 14 weeks	Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies. The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores.
Norketamine Cmax (Measured in ng/mL).	At week 1	Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children.
Pain Control	Week 2	Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well. Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain.